iOnctura

iOnctura, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin-off from Merck and is backed by M Ventures. It is a clinical-stage biotechnology company focused on developing a pipeline of next-generation, first-in-class molecules at the forefront of groundbreaking new cancer therapies. iOnctura has a carefully selected portfolio of assets licensed from Merck and UK. Its oncology programs aim to harness both immune-mediated and direct anti-tumor activity to deliver superior clinical efficacy as monotherapies or combination therapies. By leveraging complementary mechanisms between cancer and fibrosis, iOnctura is further committed to addressing highly unmet needs in fibrotic diseases.